My watch list
my.bionity.com  
Login  

Tofacitinib for the treatment of moderate-to-severe psoriasis

Because of the increased knowledge about the underlying cytokine network in psoriasis, selective systemic agents for the treatment of moderate-to-severe psoriasis have been developed during the past decade. The marked upregulation of JAK/STAT pathways in psoriasis and the identification of multiple key mediators in psoriasis pathogenesis that signal through JAK/STAT pathways led to investigation of JAK proteins as potential therapeutic targets for psoriasis treatment. A novel JAK-STAT inhibitor, tofacitinib, has been tested in preclinical studies for the treatment of psoriasis. Considering the satisfactory safety profile and the encouraging efficacy observed in the Phase II and Phase III trials, tofacitinib may represent an important therapeutic to be included into the psoriasis paradigm.

Authors:   Andrea Chiricozzi; Sara Faleri; Rosita Saraceno; Luca Bianchi; Oreste Buonomo; Sergio Chimenti; Maria Sole Chimenti
Journal:   Expert Review of Molecular Diagnostics
Year:   2015
DOI:   10.1586/1744666X.2015.1013534
Publication date:   10-Feb-2015
Facts, background information, dossiers
More about Expert Reviews
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE